Immutep Limited IMMP
Updated: 10 Aug 2026
No signal published yet
We already track Immutep and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Immutep Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immutep free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In its Q4 FY26 activities report published on July 30, 2026, Immutep reported A$68.87 million in cash, cash equivalents, and term deposits. The company implemented cost-reduction measures designed to extend its cash runway into the first half of 2028. The report also detailed updated clinical data for its lead candidates eftilagimod alfa and IMP761.
What Firelda Watch includes for Immutep Limited
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Immutep Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immutep free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more